TrialInternational journal of clinical oncology2025

Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.

Hideki Goto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.